Saint Alphonsus Medical Center-Ontario

Summary

Saint Alphonsus Medical Center-Ontario is a medical facility located in Ontario, Oregon. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Saint Alphonsus Medical Center-Ontario is involved with conducting 185 clinical trials across 331 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.

Top PIs

Clinical Trials running at Saint Alphonsus Medical Center-Ontario

Bladder Cancer

Lung Cancer

Breast Cancer

Cancer

Breast cancer

Ovarian Cancer

Prostate Cancer

Bladder Carcinoma

Multiple Myeloma

Melanoma

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Gemcitabine + Docetaxel vs BCG

for Bladder Cancer

This trial is testing whether a combination of two drugs, Gemcitabine and Docetaxel, given directly into the bladder, is effective for patients with high-grade non-muscle invasive bladder cancer who have not been treated with the standard therapy before. The goal is to see if this new treatment can prevent cancer from coming back or spreading. The study will also look at the quality of life, safety, and side effects of the new treatment. Gemcitabine and Docetaxel have shown promise as an alternative treatment, especially in cases where the standard therapy fails or is not tolerated.

Recruiting

2 awards

Phase 3

14 criteria

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria